MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$132,089K
Net Income
$3,113K
Net Profit Margin
2.36%
EPS
$0.04
Unit: Thousand (K) dollars
Revenue Breakdown
US
Non Us
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-28
2025-12-31
2025-09-27
2025-06-28
Net sales
132,089
157,900
138,651
147,660
Cost of sales (including depreciation and amortization of 10,087 and 10,265, respectively)
41,320
49,118
44,422
45,570
Gross profit
90,769
108,782
94,229
102,090
Selling, general and administrative expense
78,325
82,757
78,657
79,110
Research and development expense
2,467
3,007
2,923
3,172
Restructuring costs
454
2,235*
-
-
Change in fair value of contingent consideration
-
0*
0
0
Depreciation and amortization
1,107
1,297
1,398
1,439
Impairment of assets
-
0*
0
0
Loss on disposals
0
0
1
-1
Operating income
8,416
19,486
11,252
18,368
Interest expense, net
-4,326
-5,306
-6,177
-7,494
Gain on extinguishment
-
0
-326
-
Other (income) expense
427
-37
-79
-561
Other expense
-3,899
-5,343
-6,582
-8,055
Income (loss) before income taxes
4,517
14,143
4,670
10,313
Income tax expense (benefit), net
571
-3,175
664
1,041
Net income (loss) from continuing operations
-
17,318*
-
-
Loss from discontinued operations, net of tax
-
0*
-
-
Net income (loss)
3,946
17,318
4,006
9,272
(income) loss attributable to noncontrolling interest - continuing operations
-
2,563*
-
-
Loss attributable to noncontrolling interest - discontinued operations
-
0*
-
-
(income) loss attributable to noncontrolling interest
833
-
851
1,813
Net income (loss) attributable to bioventus inc
3,113
14,755
3,155
7,459
Basic EPS
0.05
0.22
0.05
0.11
Diluted EPS
0.04
0.204
0.05
0.11
Basic Average Shares
67,296,336
67,056,726
66,924,682
66,500,433
Diluted Average Shares
70,008,291
72,276,341
68,837,797
68,536,759
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Pain Treatments
$56,157K
(6.59%↑ Y/Y)
Surgical Solutions
$42,541K
(4.15%↑ Y/Y)
Restorative Therapies
$17,747K
(4.46%↑ Y/Y)
Pain Treatments
$7,269K
(16.64%↑ Y/Y)
Surgical Solutions
$5,487K
(24.99%↑ Y/Y)
Restorative Therapies
$2,888K
(5.63%↑ Y/Y)
US
$116,445K
(5.36%↑ Y/Y)
Non Us
$15,644K
(17.13%↑ Y/Y)
Net sales
$132,089K
(6.63%↑ Y/Y)
Gross profit
$90,769K
(9.29%↑ Y/Y)
Cost of sales
(including depreciation...
$41,320K
(1.22%↑ Y/Y)
Operating income
$8,416K
(72.85%↑ Y/Y)
Selling, general and
administrative expense
$78,325K
(6.56%↑ Y/Y)
Research and development
expense
$2,467K
(-18.07%↓ Y/Y)
Depreciation and
amortization
$1,107K
(-30.51%↓ Y/Y)
Restructuring costs
$454K
Income (loss) before
income taxes
$4,517K
(232.19%↑ Y/Y)
Other expense
-$3,899K
(52.94%↑ Y/Y)
Other (income)
expense
$427K
(154.95%↑ Y/Y)
Net income (loss)
$3,946K
(218.78%↑ Y/Y)
Income tax expense
(benefit), net
$571K
(701.05%↑ Y/Y)
Interest expense, net
-$4,326K
(42.39%↑ Y/Y)
Net income (loss)
attributable to bioventus inc
$3,113K
(218.05%↑ Y/Y)
(income) loss
attributable to...
$833K
(221.61%↑ Y/Y)
Buy us a coffee
Bioventus Inc. (BVS)
Bioventus Inc. (BVS)